<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005070A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005070</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>14004623</doc-number><date>20120328</date></document-id></application-reference><us-application-series-code>14</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>Q</subclass><main-group>1</main-group><subgroup>68</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>Q</subclass><main-group>1</main-group><subgroup>6881</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>506  9</main-classification></classification-national><invention-title id="d0e43">MARKERS ASSOCIATED WITH CYCLIN-DEPENDENT KINASE INHIBITORS</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61468452</doc-number><date>20110328</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Faure</last-name><first-name>Michel</first-name><address><city>Oakland</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>Gao</last-name><first-name>Zhenhai</first-name><address><city>Orinda</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>Sutton</last-name><first-name>James</first-name><address><city>Pleasanton</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant" designation="us-only"><addressbook><last-name>Yu</last-name><first-name>Guoying Karen</first-name><address><city>Kensington</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Faure</last-name><first-name>Michel</first-name><address><city>Oakland</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Gao</last-name><first-name>Zhenhai</first-name><address><city>Orinda</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Sutton</last-name><first-name>James</first-name><address><city>Pleasanton</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Yu</last-name><first-name>Guoying Karen</first-name><address><city>Kensington</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Novartis AG</orgname><role>03</role><address><city>Basel</city><country>CH</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/IB2012/051482</doc-number><kind>00</kind><date>20120328</date></document-id><us-371c124-date><date>20130911</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) markers in a patient treated with a Cyclin Dependent Kinase Inhibitor (CDKI), methods of determining the sensitivity of a cell to a CDKI by measuring PD markers and methods of screening for candidate CKDI.</p></abstract></us-patent-application>